Nanosphere's respiratory virus subtyping test gets FDA go-ahead
This article was originally published in Clinica
Executive Summary
A test developed by Nanosphere to detect different types of respiratory viruses has received 510(k) clearance from the US FDA. The Verigene respiratory virus plus nucleic acid test (RV+) can identify influenza A and B, and respiratory syncytial virus (RSV) A and B. It also further classifies influenza A infections as H1, H3 or the 2009 H1N1 subtype. The test runs on the firm's Verigene system. The RV+ automates several testing steps including viral RNA extraction, multiplexed RT-PCR amplification and target detection, and only requires a single pipetting step. Northbrook, Illinois-based Nanosphere claims the product offers "the broadest respiratory panel available".
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.